COPENHAGEN, March 21 (Reuters) - Denmark's Novonensis , created from the merger of food ingredients and enzymes makers Novozymes and Chr. Hansen, on Thursday predicted a 2024 adjusted margin on its earnings before interest, tax, depreciation and amortization of around 35%.

In 2023, the proforma EBITDA margin for the combined group stood at 33.8%, the company said in a statement.

The company forecast organic sales growth of between 5% and 7% this year, after growing by 7% in 2023, it said in a statement.

"We expect a solid 2024 performance... and a strong margin development," Novonensis said. (Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)